FDA Approval Summary: Repotrectinib for Locally Advanced or Metastatic ROS1-Positive Non–Small Cell Lung CancerMichael I. Barbato, Nicole Drezner, Jeanne Fourie Zirkelbach et al.|Clinical Cancer Research|2024Cited by 13